The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Ironwood Pharmaceuticals (I)
Honoraria - Agios; Amgen; ARIAD/Takeda; Array BioPharma; Blueprint Genetics; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Gilead Sciences; Incyte; Lilly; Loxo; Merck; Novartis; Oncorus; Pfizer; Regeneron
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD/Takeda; Array BioPharma (Inst); Blueprint Genetics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis; Novartis (Inst); Tesaro (Inst)
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
 
Salma K. Jabbour
Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Merck Sharp & Dohme (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Emilio Bria
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Merck Sharp & Dohme; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono; Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
 
Jaishree Bhosle
No Relationships to Disclose
 
Justin F. Gainor
No Relationships to Disclose
 
Noemi Reguart
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; Lilly; MSD Oncology; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; MSD; Roche; Roche Molecular Diagnostics
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - MSD; Roche
 
Luhua Wang
No Relationships to Disclose
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; G1 Therapeutics; Gilead Sciences; PharmaMar; Takeda
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst)
 
Ellen Gurary
Employment - Merck Sharp & Dohme
 
Tanya B. Ashraf
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Humberto Lara-Guerra
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Aeglea Biotherapeutics; Merck Sharp & Dohme
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech